FDA Clearance Tracker · P200048
IsoPSA Assay
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Nov 28, 2025
Approved
Time to decision
1,796 days
Received Dec 28, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P200048
- Device name
- IsoPSA Assay
- Applicant
- Cleveland Diagnostics, Inc.
- Applicant location
- Cleveland, OH
- Received
- Dec 28, 2020
- Decided
- Nov 28, 2025
- Decision
- Approved
- Supplements
- 1 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Multi-analyte test system with algorithmic analysis for detection of prostate cancer (QRF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the IsoPSA Assay.The IsoPSA Assay is an in vitro test system that combines the results of total Prostate Specific Antigen (PSA) (Elecsys, Roche Diagnostics) and free PSA (Elecsys, Roche Diagnostics) from partitioned heparinized plasma into a single numerical index. The IsoPSA Assay is indicated for use in conjunction with other patient information to aid in detection of high-grade prostate cancer (Grade Group >= 2; Gleason score >= 7) in men >= 50 years of age, with total PSA levels >= 4.0 to =< 10.0 ng/mL for whom a biopsy is being considered by a urologist based on current standard of care, before consideration of IsoPSA Assay results.Prostatic biopsy is required for the diagnosis of cancer.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QRF. The earliest in FDA's data is P190022, decided Dec 7, 2021.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for Cleveland Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.